吉西他滨与顺铂联合治疗晚期非小细胞肺癌的临床疗效

目的 :观察以吉西他滨 (Gem)为主的联合化疗方案治疗晚期非小细胞肺癌 (NSCL C)的临床疗效和不良反应。方法 :Gem与顺铂 (Cis)化疗组 (A组 ) 13例 :Gem10 0 0 m g/ m2 ,d1、8、15 iv gtt,qd;Cis80 m g/ m2 ,分 3d,iv gtt,水化 ,2 1d为 1个周期。丝裂霉素 (Mit)、长春地辛 (Vin)和 Cis化疗组 (B组 ) 2 4例 :Mit8mg/ m2 ,d1iv;Vin3m g/ m2 ,d1、8、15 iv gtt,qd;Cis80 mg/ m2 ,分 3d iv gtt,水化 ,2 1d为 1个周期。治疗 2个周期评价疗效。结果 :A组部分缓解 7例 ,无变化 5例 ,进展 1例 ,总有效率 5 3.8%。 B组部分缓解 10例 ,无变化 10例 ,进展 4例 ,总有效率 41.7%。 2组疗效比较差异有显著意义 (P<0 .0 5 ) ,且A组骨髓抑制及消化道不良反应相对较轻 (P<0 .0 5 )。结论 :Gem和 Cis联合化疗治疗晚期 NSCL C具有较好的疗效 ,不良反应轻。

Clinical trial of advanced non-small cell lung cancer by combination of gemci tabine and cisplatin

AIM: To evaluate the efficacy and toxicity of the chemotherapy combining gemcitabine (Gem) and cisplatin (Cis) in advanced non small cell lung cancer (NSCLC). METHODS: Two treatment cycles with 21 d for each cycle were needed. Gem Cis combination study (A group): the dosage was 1 000 mg/m 2, iv gtt, qd, at d 1, 8, 15 for Gem and 80 mg/m 2, iv gtt, qd, at d 1, 2, 3 for Cis respectively. Mitomycin (Mit), vindesine (Vin) plus Cis combination study (B group): the dosage was 8 mg/m 2, iv gtt, at d 1 for Mit, 3 mg/m 2, iv gtt, qd, at d 1, 8, 15 for Vin and 80 mg/m 2 iv gtt, qd, at, d 1, 2, 3 for Cis respectively. RESULTS: A group of total 13 cases, 7 got partial remission, 5 no change, 1 progression of diease, and the efficiency rate was 53 8% in A group. B group: the total 24 cases, 10 got partial remission, 10 no change, 4 progression of disease, and the efficiency rate was 41 7%. For comparison, significant difference was observed in efficacy between combination chemotherapy of Gem plus Cis and Mit, Vin plus Cis ( P<0 05 ), and the bone marrow suppression and gastrointestinal tract adverse drug reactions for combination with Gem plus Cis were relatively weak ( P <0 05). CONCLUSION: The combined chemotherapy of Gem and Cis, with its low toxicity and high tolerance, is an ideal regimen for advanced NSCLC.